@article {Frost2020.05.18.20105239, author = {Isabel Frost and Katie Tseng and Stephanie Hauck and Geetanjali Kapoor and Aditi Sriram and Arindam Nandi and Ramanan Laxminarayan}, title = {Risks to Children under-five in India from COVID-19}, elocation-id = {2020.05.18.20105239}, year = {2020}, doi = {10.1101/2020.05.18.20105239}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Objective The novel coronavirus, COVID-19, has rapidly emerged to become a global pandemic and is known to cause a high risk to patients over the age of 70 and those with co-morbidities, such as hypertension and diabetes. Though children are at comparatively lower risk compared to adults, the Indian population has a large young demographic that is likely to be at higher risk due to exposure to pollution, malnutrition and poor access to medical care. We aimed to quantify the potential impact of COVID-19 on India{\textquoteright}s child population.Methods We combined district family household survey data with data from the COVID-19 outbreak in China to analyze the potential impact of COVID-19 on children under the age of 5, under three different scenarios; each of which assumed the prevalence of infection to be 0.5\%, 1\%, or 5\%.Results We find that in the lowest prevalence scenario, across the most populous 18 Indian states, asymptomatic, non-hospitalized symptomatic and hospitalized symptomatic cases could reach 87,200, 412,900 and 31,900, respectively. In a moderate prevalence scenario, these figures reach 174,500, 825,800, and 63,800, and in the worst case, high prevalence scenario these cases could climb as high as 872,200, 4,128,900 and 319,700.Conclusion These estimates show COVID-19 has the potential to pose a substantial threat to India{\textquoteright}s large population of children, particularly those suffering from malnutrition and exposure to indoor air pollution, who may have limited access to health services.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAuthors did not receive funding specific to this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in the study is available from public databases as listed in the methods section of the paper.}, URL = {https://www.medrxiv.org/content/early/2020/05/22/2020.05.18.20105239}, eprint = {https://www.medrxiv.org/content/early/2020/05/22/2020.05.18.20105239.full.pdf}, journal = {medRxiv} }